Contraindicated in:
Use Cautiously in:
CV: palpitations.
Derm: pruritus.
EENT: vertigo.
GI: abdominal pain, anorexia, nausea, vomiting, diarrhea, hepatomegaly, splenomegaly.
GU: ↓ fertility.
Hemat: anemia.
MS: arthralgia, myalgia.
Neuro: dizziness, fatigue, headache, sleep disorder, weakness, insomnia, malaise.
Resp: cough.
Misc: chills, fever, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS, URTICARIA, AND ANGIOEDEMA).
Drug-Drug:
Drug-Natural Products:
Drug-Food:
Absorption: Well absorbed following oral administration, food increases absorption. Artemether is a prodrug that is rapidly converted to Dihydroartemisinin (DHA), an active antimalarial compound.
Distribution: Unknown.
Protein Binding: Lumefantrine: 99.7%.
Metabolism/Excretion: Extensively metabolized by the liver. Artemether is primarily metabolized by CYP3A4/5. Lumefantrine is metabolized mainly by CYP3A. Lumefantrine also significantly inhibits CYP2D6.
Half-life: Artemether and DHA: 2 hr; lumefantrine: 36 days.
(antimalarial effect)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
artemether PO | unknown | 2 hr | hrs |
lumefantrine PO | unknown | 68 hr | days |
Blood levels.